Likewise! Its not an outright rejection, because if you read the regulations - https://www.ecfr.gov/cgi-bin/text-idx?SID=267602869dc495c1d59379706cf83c90&mc=true&node=se21.5.314_1110&rgn=div8 and
the reasons for an NDA refusal here - https://www.ecfr.gov/cgi-bin/text-idx?SID=267602869dc495c1d59379706cf83c90&mc=true&node=se21.5.314_1125&rgn=div8
The FDA just wants more evidence. Its not a rejection of the current evidence.
Its stem cells. Its a revolutionary method here.
The best case scenario is to see approval via the accelerated approval pathway, and then a post-marketing study as a condition in the approval.
This I believe will be given because its a huge unmet need!
Likewise! Its not an outright rejection, because if you read the...
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |